| Private Placement / Financing Transactions
Pathos: The company raised $365 million of Series D venture funding from undisclosed investors on May 15, 2025, putting the company’s pre-money valuation at $1.24 billion. The company is a developer of a drug discovery platform designed to reduce the duration of the medication development process.
Azafaros: The company raised EUR 132 million of Series B venture funding in a deal led by Jeito and Forbion on May 13, 2025. BioGeneration Ventures, Seroba Life Sciences, Pictet, and Schroders Capital also participated in the round. The company is a developer of therapeutic agents designed for the treatment of rare metabolic disorders through oral administration of aza-sugar compounds.
Cohere Health: The company raised $90 million of Series C venture funding in a deal led by Temasek Holdings on May 14, 2025, putting the company’s pre-money valuation at $660 million. Flare Capital Partners, Define Ventures, Polaris Partners, Longitude Capital, Deerfield Management, and other undisclosed investors also participated in the round. The company is an operator of a clinical intelligence business delivering AI-powered intelligent prior authorization solutions.
Stylus Medicine: The company raised $85 million of Series A venture funding from Chugai Venture Fund, Eli Lilly and Company, and Johnson & Johnson Innovation – JJDC on May 14, 2025. Tachyon Ventures, Myeloma Investment Fund, Khosla Ventures, Brainstorm Ventures, RA Capital Management, and other undisclosed investors also participated in the round. The company is an operator of a biotechnology research business intended to develop next-generation vivo genetic medicines.
Akido Labs: The company raised $84.3 million of Series B venture funding in a deal led by Oak HC/FT on May 16, 2025. Comprehensive Blood & Cancer Center, Greco Aluminum Railings, SNR, Future Communities Capital, Y Combinator, SaaS Ventures and Jeff Dean also participated in the round. The company is a developer of an AI-powered healthcare system which operates as a clinical assistant.
Therini Bio: The company raised $75 million of Series A venture funding and debt in a deal led by MRL Ventures Fund, Sanofi Ventures and SV Health Investors on May 14, 2025, putting the company’s pre-money valuation at $41.7 million. Foundation For a Better World, Eli Lilly and Company, Angelini Ventures, Apollo Health Ventures, Dreavent, Dolby Family Ventures, Alzheimers Drug Discovery Foundation, Blue Goose Capital and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business intended to offer a treatment to protect the nervous system from multiple sclerosis damage.
Alpheus Medical: The company raised $52 million of Series B venture funding in a deal led by HealthQuest Capital and Samsara BioCapital on May 15, 2025, putting the company’s pre-money valuation at $88 million. Action Potential Venture Capital, OrbiMed, National Brain Tumor Society, The Sontag Foundation, BrightEdge, and other undisclosed investors also participated in the round. The company is a developer of a sonodynamic therapy device designed to treat solid tumors through non-invasive outpatient care.
Somite Therapeutics: The company raised $47 million of Series A venture funding in a deal led by Khosla Ventures on May 13, 2025, putting the company’s pre-money valuation at $108 million. Ajinomoto, Fusion Fund, SciFi VC, TechAviv Founder Partners, Harpoon Ventures, Pitango Venture Capital, Fidji Simo, Martin Chavez, Chan Zuckerberg Initiative and other undisclosed investors also participated in the round. The company is a developer of a biotechnology platform designed to transform medical treatments and therapeutic research for musculoskeletal and metabolic diseases.
Kincell Bio: The company raised $22 million of venture funding in a deal led by Kineticos Life Sciences Management and NewSpring Capital on May 15, 2025. The company is an operator of a contract development and manufacturing organization intended to advance autologous and allogeneic cell therapies for patients.
Remedy Plan Therapeutics: The company raised $18 million of venture funding from Schooner Capital and Alexandria Venture Investments on May 13, 2025. The company is a developer of medical drugs designed to halt tumor growth and prevent cancer.
WearLinq: The company raised $11.6 million in Series A venture funding from undisclosed investors on May 14, 2025, putting the company’s pre-money valuation at $49.4 million. The company is a developer of a health monitoring and diagnosis device designed to enhance patient care and clinical outcomes.
Olio: The company raised $11 million of Series B venture funding in a deal led by Fulcrum Equity Partners on May 12, 2025. Mutual Capital Partners also participated in the round. The company is an operator of a digital communication platform designed to connect acute and post-acute providers by surgical specialty.
Axis Spine Technologies: The company raised GBP 6.7 million of venture funding from Mercia Asset Management, Northern Venture Trust and Enterprise Investment Scheme on May 13, 2025, putting the company’s pre-money valuation at GBP 16.9 million. The company is a developer of implant systems that achieve and maintain superior spinal alignment for improved clinical outcomes.
Grip Molecular: The company raised $8.8 million of venture funding in the form of convertible debt from undisclosed investors on May 16, 2025. The company is a developer of a graphene-based biosensor designed to give diagnostic results in minutes using a mobile device.
UpFront: The company raised $4.3 million of venture funding through a combination of equity and grant in a deal led by Phoenix Sustainable Investments on May 15, 2025. Cambridge Enterprise Ventures and SBRI Healthcare also participated in the round. The company is a developer of rapid diagnostic tests designed for stroke identification.
AlfaDocs: The company raised EUR 3.7 million of Series A venture funding from BayBG Venture Capital, Bayern Kapital and SaaSgarage on May 14, 2025. Achim Lederle, Alexander Bruehl, Stefan Alois Margolis, Kai Romberg and Sascha Pfeiffer also participated in the round. The company is a developer of enterprise management software designed to streamline medical practice management.
Sea Pharmaceuticals: The company is in the process of raising venture funding on May 14, 2025. The company is a developer of a neurotherapeutics company focused on developing novel, orally administered treatments for central nervous system (CNS) disorders.
|
